Thress, Kenneth S
Paweletz, Cloud P
Felip, Enriqueta
Cho, Byoung Chul
Stetson, Daniel
Dougherty, Brian
Lai, Zhongwu
Markovets, Aleksandra
Vivancos, Ana
Kuang, Yanan
Ercan, Dalia
Matthews, Sarah E
Cantarini, Mireille
Barrett, J Carl
Jänne, Pasi A
Oxnard, Geoffrey R
Article History
Received: 13 January 2015
Accepted: 9 April 2015
First Online: 4 May 2015
Competing interests
: K.S.T., D.S., B.D., Z.L., A.M., M.C. and J.C.B. are employees of AstraZeneca. E.F. has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, Eli Lilly, Pfizer, and Roche. B.C.C. has received consulting fees from Boehringer-Ingelheim, GlaxoSmithKline, and Novartis and has received research grants from AstraZeneca, Bayer, Boehringer-Ingelheim, and Novartis. P.A.J. has received consulting fees from AstraZeneca, Boehringer-Ingelheim, Clovis, Chugai, and Genentech; is co-inventor on a patent held by the Dana-Farber Cancer Institute for the use of <i>EGFR</i> genotyping; and receives a share of post-market licensing revenue distributed by Dana-Farber Cancer Institute. G.R.O. has received consulting fees from AstraZeneca, Boehringer-Ingelheim, Clovis, Genentech, Novartis, and Sysmex. All other authors have no disclosures.